drugset / Trial / NCT03055312
Bicalutamide in Treatment of Androgen Receptor (AR) Positive Metastatic Triple Negative Breast Cancer
RandomizedParallel-groupOpen-labelPrevention
Summary
Compare the efficacy of bicalutamide with conventional chemotherapy (Treatment of Physician's Choice,TPC) in first-line treatment of AR positive metastatic triple negative breast
Timeline
- Start
- 2016-12-20
- Primary completion
- 2020-11-15
- Completion
- 2020-11-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bicalutamide | Other / unclassified | 150 mg | — |
| Comparator | Capecitabine | Small molecule | 950 mg/m2 | Oral |
| Comparator | Carboplatin | Small molecule | — | Intravenous |
| Comparator | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |
| Comparator | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |
| Comparator | Gemcitabine | Small molecule | 1250 mg/m2 | Intravenous |
| Comparator | Paclitaxel | Small molecule | 175 mg/m2 | Intravenous |